BFRG News & Events

BullFrog AI issued a letter to shareholders from founder and CEO Vin Singh stating the company has secured the financial runway to execute its strategy into late 2027 and is in active discussions with pharmaceutical and biotechnology organizations. "BullFrog AI enters the second quarter of 2026 well-capitalized, at commercial stage, and in active discussions with consequential pharmaceutical and biotechnology organizations," said Vin Singh, founder and CEO. "We just closed our first agreement with a top 5 global pharmaceutical company, secured the financial runway to execute our strategy into late 2027, and are deeply engaged with an industry that is no longer evaluating whether to embrace AI-driven drug discovery - but deciding with whom".

BullFrog AI announced a commercial agreement with a global pharmaceutical company to apply the company's proprietary bfLEAP platform to identify and prioritize novel drug targets in major depressive disorder, accelerating the customer's drug discovery and clinical development program for this indication. The agreement also provides exclusive access to a target candidate

BullFrog AI Holdings announces the coming launch of a new scenario-based decision engine for pharmaceutical portfolio strategy and clinical trial design. Key capabilities include: Compares drug programs, indications, and trial designs without forcing arbitrary numerical scores; Tests portfolio decisions against multiple explicit scenarios; Identifies options that perform well across strategic futures; Preserves portfolio diversity while surfacing clear leaders to balance concentration with risk mitigation